Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 5/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21089 | 0.84 | MIF (0.44) | MIFTRPA1CYP3A4TSHRALDH1A1 | |
| SCHEMBL18486425 | 0.83 | CA1 (0.39) | MIFTRPA1CYP3A4TSHRALDH1A1 | |
| Water SCHEMBL14972874 | 0.82 | MIF (0.43) | MIFTRPA1CYP3A4TSHRALDH1A1 | |
| Water SCHEMBL29040332 | 0.82 | MIF (0.43) | MIFTRPA1CYP3A4TSHRALDH1A1 | |
| SCHEMBL22471901 | 0.82 | MIF (0.43) | MIFTRPA1CYP3A4TSHRALDH1A1 | |
| SCHEMBL18567327 | 0.81 | MIF (0.42) | MIFTRPA1CYP3A4TSHRALDH1A1 | |
| SCHEMBL28911026 | 0.79 | MIF (0.39) | MIFTRPA1CYP3A4TSHRALDH1A1 | |
| SCHEMBL151739 | 0.78 | MIF (0.44) | MIFTRPA1ALDH1A1 | |
| SCHEMBL31094964 | 0.78 | MIF (0.40) | MIFTRPA1CYP3A4TSHRALDH1A1 | |
| Cyclohexane SCHEMBL28302863 | 0.78 | MIF (0.40) | MIFTRPA1CYP3A4TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | MIF 33/4885TRPA1 1737/4885CYP3A4 3993/4885 |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | MIF 33/4885TRPA1 1737/4885CYP3A4 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.